MedTrace Logo

Phase II Study of TAK228 in Relapsed Lymphoma

NCT02727777 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-03-12

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.

Conditions

Interventions

DRUG

TAK228

Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.

OTHER

Blood Sugar Testing

Participant given a glucometer to check pre-dose blood sugar levels at home every day.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jason R. Westin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-07-10
Completion
2018-07-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727777 on ClinicalTrials.gov